Related references
Note: Only part of the references are listed.A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers
Jianyu Cai et al.
ONCOTARGET (2017)
Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition
Magdalena Mazurkiewicz et al.
ONCOTARGET (2017)
The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5
You-Take Oh et al.
SCIENTIFIC REPORTS (2017)
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
Neerav Shukla et al.
CANCER RESEARCH (2016)
Ubiquitin-specific protease 14 regulates cell proliferation and apoptosis in oral squamous cell carcinoma
Xiangyun Chen et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2016)
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
Olivier Hermine et al.
LANCET (2016)
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells
A. Paulus et al.
BLOOD CANCER JOURNAL (2016)
USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment
Rachel Isaksson Vogel et al.
ONCOTARGET (2016)
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
Xin Wang et al.
SCIENTIFIC REPORTS (2016)
Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenstroom macroglobulinaemia tumour cells
Kasyapa Chitta et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15
Xin Wang et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2015)
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Tadeusz Robak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
USP14 activation promotes tumor progression in hepatocellular carcinoma
Gang Huang et al.
ONCOLOGY REPORTS (2015)
Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I
Guang Yang et al.
ONCOTARGET (2015)
Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells
Rachel Isaksson Vogel et al.
ONCOTARGET (2015)
Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology Basel, 9th-13th October 2015 Abstracts
[Anonymous]
Oncology Research and Treatment (2015)
Mantle cell lymphoma: evolving management strategies
Elias Campo et al.
BLOOD (2015)
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance
Ze Tian et al.
BLOOD (2014)
Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells
Xiaoli Feng et al.
EXPERIMENTAL HEMATOLOGY (2014)
Regulation of Ligands for the NKG2D Activating Receptor
David H. Raulet et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells
Dhifaf Sarhan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome
Liang Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2013)
New prospects on the NKG2D/NKG2DL system for oncology
Evelyn Ullrich et al.
ONCOIMMUNOLOGY (2013)
Proteasome inhibitors in multiple myeloma: 10 years later
Philippe Moreau et al.
BLOOD (2012)
Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
Julia Hilpert et al.
JOURNAL OF IMMUNOLOGY (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
Patricia Perez-Galan et al.
BLOOD (2011)
Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation
Benjamin J. Schmiedel et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
Padraig D'Arcy et al.
NATURE MEDICINE (2011)
Proteasome inhibitors in cancer therapy
Lisa J. Crawford et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2011)
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
Alessandra Soriani et al.
BLOOD (2009)
Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity
Xiangling Wang et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Natural killer cell cytotoxicity: how do they pull the trigger?
Nicola J. Topham et al.
IMMUNOLOGY (2009)
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Annina Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Proteasome Regulation of ULBP1 Transcription
James E. Butler et al.
JOURNAL OF IMMUNOLOGY (2009)
Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors
Mar Vales-Gomez et al.
CANCER RESEARCH (2008)
Direct and natural killer cell-mediated antitumor effects of low-dose Bortezomib in hepatocellular carcinoma
Sorin Armeanu et al.
CLINICAL CANCER RESEARCH (2008)
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition
William H. D. Hallett et al.
JOURNAL OF IMMUNOLOGY (2008)
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics
Pedro Jares et al.
NATURE REVIEWS CANCER (2007)
Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions
Katrin M. Baltz et al.
FASEB JOURNAL (2007)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity
Andreas Lundqvist et al.
CANCER RESEARCH (2006)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
HR Salih et al.
BLOOD (2003)
Share Paper
